Emisphere Technologies Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/30/2017)
| Balance Sheet | Total Assets | 6,584,000.00 | ROE | – |
| Balance Sheet | Total Equity | -161,408,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -6,813,001.00 | – | – |
| Cashflow | Operating Cash Flow | -6,813,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.17 | Div. Yield | – |
| Income | Net Income | -10,041,000.00 | P/E | – |
| Income | Shares Outstanding | 60,687,500.00 | P/B | – |
| Income | Total Revenue | 1,195,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.emisphere.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more